NUTLEY, N.J., Nov. 7 /PRNewswire/ -- New data on Roche's innovative investigational anti-anemia agent CERA (Continuous Erythropoietin Receptor Activator) will be presented at the American Society of Nephrology 38th Annual Meeting & Scientific Exposition -- Renal Week in Philadelphia on Nov. 8th - 13th. The data provide further insight into the fundamental activity of CERA and give more perspective on its emerging clinical profile.
The studies to be presented are: -- New data on the control of anemia achieved with long-term use of CERA given at extended dosing intervals in chronic kidney disease (CKD) patients not on dialysis. -- First presentation of data on the pharmacological profile of CERA, which detail the half-life of the agent when given via subcutaneous or intravenous routes in CKD patients on peritoneal dialysis. -- Insight into the use of subcutaneous CERA in the clinical setting regarding consistency of CERA activity regardless of the site of injection. -- The relationship between CERA dosing and its erythropoiesis stimulating activity in CKD patients not on dialysis.
Roche has undertaken the largest phase II - III program ever for a drug treating renal anemia with 10 trials involving more than 2,700 patients. It is currently nearing completion of Phase III of its development in CKD and Roche aims to file CERA in the U.S. and worldwide in 2006.
Interested journalists may view the text of the ASN abstracts selected for presentation, as well as the meeting schedule on-line at http://www.asn-online.org/.
RocheCONTACT: Shelley Rosenstock, Roche, +1-973-562-2373, Cell:+1-973-476-7201, shelley.rosenstock@roche.com; Harriet Shelare, ManningSelvage & Lee, +1-212-468-3612, Cell: +1-917-653-9714,harriet.shelare@mslpr.com
Web site: http://www.asn-online.org/
